AVEO Pharmaceuticals (AVEO Pharmaceuticals) Inventory-to-Revenue : 0.04 (As of Sep. 2022)

View and export this data going back to 2010. Start your Free Trial

What is AVEO Pharmaceuticals Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. AVEO Pharmaceuticals's Average Total Inventories for the quarter that ended in Sep. 2022 was $1.21 Mil. AVEO Pharmaceuticals's Revenue for the three months ended in Sep. 2022 was $30.45 Mil. AVEO Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Sep. 2022 was 0.04.

AVEO Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Sep. 2022 declined from Jun. 2022 (0.06) to Jun. 2022 (0.04)

A decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. AVEO Pharmaceuticals's Days Inventory for the three months ended in Sep. 2022 was 27.92.

Inventory Turnover measures how fast the company turns over its inventory within a year. AVEO Pharmaceuticals's Inventory Turnover for the quarter that ended in Sep. 2022 was 3.27.

AVEO Pharmaceuticals Inventory-to-Revenue Historical Data

The historical data trend for AVEO Pharmaceuticals's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVEO Pharmaceuticals Inventory-to-Revenue Chart

AVEO Pharmaceuticals Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Inventory-to-Revenue

Get a 7-Day Free Trial

0.04

AVEO Pharmaceuticals Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Inventory-to-Revenue	Get a 7-Day Free Trial															0.08	0.08	0.08	0.06	0.04

Competitive Comparison of AVEO Pharmaceuticals's Inventory-to-Revenue

For the Biotechnology subindustry, AVEO Pharmaceuticals's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AVEO Pharmaceuticals's Inventory-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AVEO Pharmaceuticals's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where AVEO Pharmaceuticals's Inventory-to-Revenue falls into.

AVEO Pharmaceuticals Inventory-to-Revenue Calculation

AVEO Pharmaceuticals's Inventory-to-Revenue for the fiscal year that ended in Dec. 2021 is calculated as

	Inventory-to-Revenue (A: Dec. 2021 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (A: Dec. 2020 )	+	Total Inventories (A: Dec. 2021 ))	/	count )	/	Revenue (A: Dec. 2021 )
=	( (0	+	1.656)	/	1 )	/	42.295
=	1.656					/	42.295
=	0.04

AVEO Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Sep. 2022 is calculated as

	Inventory-to-Revenue (Q: Sep. 2022 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (Q: Jun. 2022 )	+	Total Inventories (Q: Sep. 2022 ))	/	count )	/	Revenue (Q: Sep. 2022 )
=	( (1.32	+	1.106)	/	2 )	/	30.449
=	1.213					/	30.449
=	0.04

AVEO Pharmaceuticals (NAS:AVEO) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

AVEO Pharmaceuticals's Days Inventory for the three months ended in Sep. 2022 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Sep. 2022 )	/	Cost of Goods Sold (Q: Sep. 2022 )	*	Days in Period
	=	1.213	/	3.964	*	365 / 4
	=	27.92

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

AVEO Pharmaceuticals's Inventory Turnover for the quarter that ended in Sep. 2022 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Sep. 2022 )	/	Average Total Inventories (Q: Sep. 2022 )
	=	3.964	/	1.213
	=	3.27

AVEO Pharmaceuticals Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of AVEO Pharmaceuticals's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

AVEO Pharmaceuticals (AVEO Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AVEO Pharmaceuticals Inc (NAS:AVEO) » Definitions » Inventory-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

30 Winter Street, Boston, MA, USA, 02108

Website

https://www.aveooncology.com

AVEO Pharmaceuticals Inc is a commercial-stage, oncology-focused biopharmaceutical company engaged in offering medicines that provide a better life for patients with cancer. The company markets FOTIVDA (tivozanib) in the United States. FOTIVDA is an oral, next-generation vascular endothelial growth factor receptor, or VEGFR, tyrosine kinase inhibitor, or TKI. The group primarily operates in the U.S.

Executives

Jebediah Ledell	officer: Chief Operating Officer	C/O AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108
Michael P Bailey	director, officer: President & CEO	IMCLONE SYSTEMS INCORPORATED, 180 VARICK STREET, 6TH FLOOR, NEW YORK NY 10014
Michael Ferraresso	officer: Chief Commercial Officer	AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108
Kevin Joseph Cullen	director	AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108
Epperly Corinne	director	AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108
Peter W. Sonsini	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Florence Anthony A. Jr.	10 percent owner	5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Forest Baskett	10 percent owner
Joshua Makower	10 percent owner	1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Scott D Sandell	10 percent owner
Growth Equity Opportunities Iv, Llc	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Mohamad Makhzoumi	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Erick Lucera	officer: Chief Financial Officer	138 THISTLE ROAD, NORTH ANDOVER MA 08145
Scarlett Spring	director	AVEO PHARMACEUTICALS, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Peter J Barris	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202